AbbVie Inc. $ABBV Shares Purchased by Itau Unibanco Holding S.A.

Itau Unibanco Holding S.A. grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,831 shares of the company’s stock after acquiring an additional 411 shares during the quarter. Itau Unibanco Holding S.A.’s holdings in AbbVie were worth $2,010,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in shares of AbbVie during the 1st quarter valued at $688,000. Formidable Asset Management LLC boosted its position in AbbVie by 1.1% during the first quarter. Formidable Asset Management LLC now owns 10,590 shares of the company’s stock valued at $2,219,000 after purchasing an additional 119 shares during the last quarter. Finally, AMG National Trust Bank grew its stake in shares of AbbVie by 3.2% in the 1st quarter. AMG National Trust Bank now owns 22,776 shares of the company’s stock valued at $4,772,000 after buying an additional 711 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

Shares of NYSE:ABBV opened at $232.43 on Friday. The business’s 50-day moving average is $224.89 and its 200-day moving average is $203.98. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The company has a market capitalization of $410.79 billion, a price-to-earnings ratio of 110.68, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 524.24%.

Analyst Upgrades and Downgrades

Several research firms have commented on ABBV. UBS Group boosted their target price on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Hsbc Global Res cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Guggenheim boosted their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, Morgan Stanley raised their price target on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $240.14.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.